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Summary
Severe ascending aorta disease includes aneurysms, pseudoaneurysms (ascending aorta pseudoaneurysms), penetrating aortic ulcers and
Type A aortic dissections. Surgical replacement of the aortic root, ascending aorta or aortic arch is the common treatment for severe
ascending aortic disease involving the root, the ascending aorta and/or the arch. Despite good surgical results, there is still a risk for mor-
bidity and mortality following surgery for ascending aorta replacement when elderly patients or patients at high risk for surgery are con-
cerned. Less invasive endovascular treatments for ascending aorta repair are under evaluation, and some reports appeared in the available
literature in the last decade. However, clinical series or randomized studies are not yet available, and the use of these techniques is still
questionable. In this study, we analysed the outcomes of reported cases of endovascular treatment for ascending aorta disease, excluding
Type A aortic dissection. We reviewed reports published until February 2017, and we evaluated the employed technology, the devices, the
procedural steps and the outcomes. A total of 26 articles reported 67 patients (mean age 65 ± 17 years) who received endovascular treat-
ment for ascending aorta disease: aneurysms, ascending aorta pseudoaneurysms, penetrating aortic ulcers, intramural haematoma, throm-
bosis, iatrogenic coarctation and aortic rupture. Complications included endoleak (9 cases), stroke (3 cases), non-ST-elevation myocardial
infarction (1 case) and splenic infarction (1 case). Three patients required conversion to open surgery, and 1 patient underwent endovascu-
lar reintervention. Early mortality was 2.9%. As an alternative treatment for ascending aorta disease in selected high-risk patients, the endo-
vascular repair will gain popularity, but further analysis is required.
Keywords: Endovascular ascending aorta repair • Catheter-based techniques • Ascending aorta disease
INTRODUCTION
Ascending aorta disease includes several pathological findings,
such as real aneurysms, pseudoaneurysms, dissections, mural hae-
matoma, penetrating ulcers, and all are potential life-threatening
diseases requiring prompt medical and surgical treatment. The
surgical treatment represents the most valuable therapeutic
option to prevent adverse events or to save lives when aortic rup-
tures or Type A aortic dissections occur. However, despite the
low mortality rate and the good short- and long-term outcomes
of standard surgical treatment, complications and mortality rate
can still be higher as long as elderly patients, redo patients or
patients affected by severe concomitant diseases are concerned:
in a recent report of 1221 elective proximal aorta replacements,
the overall early mortality rate was 4.2% (including isolated
ascending aorta, concomitant root and concomitant arch
replacement), and it raised up to 7.9% in patients aged 70 years
or older [1]. The higher age, the chronic renal insufficiency and
previous cardiac surgery were independent predictors for
increased early mortality.
As an alternative treatment, catheter-based techniques draw
more and more attention, and, recently, they have been employed
in isolated cases or in short case series for the treatment of non-
dissected ascending aorta diseases. In the last decade, published
reports have demonstrated that the use of catheter-based techni-
ques for ascending aorta disease represent a potential life-saving
therapeutic option that provides a period of time for stable clinical
condition allowing for planning of more definitive treatments [2].
More recently, the successful use of catheter-based techniques has
been reported in Type A aortic dissection treatments and other seri-
ous ascending aorta diseases [3]. The endovascular repair of Type A
aortic dissections was previously reviewed in an earlier publication
[4]. In this review, we examined the current status of catheter-based
techniques in treating ascending aorta disease (ascending aorta
aneurysm, pseudoaneurysm, penetrating ulcer, thrombosis and rup-
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METHODS
We searched in MEDLINE with time point set to the end of
February 2017 using medical subject headings and text words
supplemented by scanning the bibliographies of retrieved
articles. We combined ‘endovascular treatment’ and ‘ascending
aorta’ using the Boolean operator ‘AND’. We used similar search
strategies using the terms ‘endovascular repair’, ‘endovascular
stent grafting’, ‘endograft repair’, ‘endovascular stent grafts’,
‘transcardiac endograft delivery’ and ‘proximal ascending aorta’.
Language was limited to articles written in English. Two coau-
thors (C.W. and L.K.v.S.) reviewed and selected relevant articles
for inclusion. Differences were resolved in consensus
discussions.
Inclusion criteria
We used ‘endovascular treatment of the ascending aorta diseases’
as the initial retrieval. All cases received endovascular stent grafts
for the ascending aorta. Only articles published in English that
reported overall morbidity and mortality data, definitive treat-
ment modalities used and configuration of catheter-based tech-
niques were included.
Exclusion criteria
All articles or cases reporting on the treatment of ascending aorta
dissection were excluded. Correspondences, expert opinion and
review were also not included.
Data extraction
We collected data on method design (retrospective or case
report), aortic disease, age, gender, case numbers, stent graft
type, access route, follow-up, complications, mortality, cause of
death and reinterventions.
Statistical analysis
Data collected were organized on an Apple Numbers (version
6.6.2) spreadsheet. Descriptive statistics were used to describe
the demographics and continuous data (e.g. mean ± standard
deviation). Dichotomous variables were expressed as numbers
with percentages.
RESULTS
The search intended for ‘endovascular treatment of the ascending
aorta’ [ti], ‘endovascular treatment’ [ti] AND ‘ascending aorta’ [ti]
showed no results. Then, we expanded the scope of retrieval with
different combinations: endovascular treatment of the ascending
aorta, endovascular treatment, endovascular repair or endovas-
cular stent grafting or endograft repair or endovascular stent
grafts or transcardiac endograft delivery AND ascending aorta.
From the initial search, 5660 articles were found. We screened
them by the title/abstract and full text. Finally, 26 articles were
selected and reviewed, spanning a period of time ranging from
2007 to 2016 (Fig. 1).
There were 6 retrospective reports and 20 case reports [5–30].
A total of 67 patients were described, with an average age of
65 ± 17 years (range 17–88 years). In the group, 44 patients were
men and 22 patients were women. One case report did not pro-
vide the patient’s gender. Three case reports did not provide data
on follow-up results (4 patients). The mean duration of follow-up
results for the remaining 63 patients was 13.4 ± 16.5months
(Table 1).
Indication for endovascular ascending aorta
treatment
Patients with aneurysm, pseudoaneurysm, penetrating aortic
ulcer and intramural haematoma localized to the ascending aorta
were included in this analysis. Also 2 ascending aorta thrombosis,
1 iatrogenic coarctation and 1 ascending aorta rupture were
included. In this analysis, the majority of patients had pseudo-
aneurysms (65.7%). The second largest patient group included
patients carrying chronic aneurysms (16.4%). The other disease
rarely occurred (Table 2). In all cases, the aortic disease affected
the segment of aorta comprised between the sinotubular junc-
tion and the innominate artery (IA) orifice, with no involvement
of the aortic valve and the aortic root. All procedures were per-
formed with endovascular stent grafting, and in few cases,
patients underwent additional procedures. To what may concern
the patients’ risk scores, only 1 case series reported EuroSCORE
data: mean of 13.5 ± 5.1 (range 8.5–23.8) [10]. None of the articles
reported the Society of Thoracic Surgeons (STS) score, and they
all report a generic ‘high-risk profile’ of included patients.
Access route
The most common access route for endovascular stent grafting
was transfemoral (32 cases, 47.7%). Twelve patients underwent
endovascular treatment through the subclavian artery (12
patients, 17.9%), and 11 procedures employed a transapical
access site route (16.4%). Other access routes included the left
carotid artery (5 cases, 7.5%), the right carotid artery (5 cases,
7.5%) and the iliac artery (2 cases, 2.9%) (Fig. 2).
Figure 1: Flow diagram illustrating identification, selection and exclusion crite-
ria for the articles used in this review.
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Table 1: Case series summary of proximal endovascular aortic procedures
Author Year AA disease Number of
cases





Kahlberg et al. [5] 2016 AA thrombosis 1 64 M Zenith TF 6 0 No No
Sakata et al. [6] 2016 AAPs 1 17 F Gore TF 12 0 No No
Khoynezhad et al. [7] 2016 AAPs/PAUs 3/1 77, 84, 67/52 M3/F1 Medtronic TF 4 17.5 (mean) 0 1 Ia leak No
1 stroke
Howell et al. [8] 2016 AAPs 1 78 F Medtronic TA 6 0 1 Ia leak No
Wada et al. [9] 2016 AAPs 1 42 M Gore LCCA 6 0 1 Ib leak No
Piffaretti et al. [10] 2016 AAPs/PAUs 5/3 57, 71, 73.65,
75/73, 81, 70
M6/F2 Gore TF 5 40 (mean) 0 1 III leak No
Zenith LSA 2
Relay RSA 1
Ahmad et al. [11] 2015 Aneurysm 1 26 F Zenith TA 12 0 No No




Shults et al. [13] 2015 AAPs 1 62 M Medtronic TA 7 0 No 1 surgical redo
Roselli et al. [14] 2015 AAPs 9 38, 84, 63, 55, 73,
63, 64, 88, 61
M7/F2 Gore TF 4 12 (mean) 0 1 leak 2 surgical redo
Cook TA 1 1 endovascular
redo
Medtronic TAX 4
Allen et al. [15] 2015 PAUs 1 88 F Valiant TA 2 0 No No
TEVAR + TAVR
Preventza et al. [16] 2014 AAPs 7 22, 59, 84, 69,
79, 82, 64





Shaikhrezai et al. [17] 2013 Aneurysm 2 59, 77 M2 Cook TF 2 66 (mean) 0 No No





Gray et al. [19] 2012 AAPs 2 65, 69 M2 Gore RCCA 2 1 0 No No
Joyce et al. [20] 2012 AAPs 3 52, 43, 68 M1/F2 Gore RCCA 1 6 0 1 III leak No
Zenith TF 2 4
36
Gelpi et al. [21] 2012 AAPs (mycotic) 1 45 M Gore TAX L 9 0 No No
Vaughan-Huxley
et al. [22]
2011 AAPs (mycotic) 1 83 F Gore TAX R 1 0 No No
Saadi et al. [23] 2011 AAPs 2 56, 74 F/M Gore TAX Not reported 0 1 Ia leak No
TEVAR + PCI TF
Kolvenbach et al. [24] 2011 Ascending
aorta disease
11 74, 71 (mean age
of 2 groups)
M5/F6 Cook Iliac 1 12.5 (mean;
range 2–20)
1 (in-hospital) 1 Ia leak 1 surgical
debranchingMedtronic RCCA 2 1 Ib leak
LCCA 2 1 Stroke
TA 2
TF 4
Zago et al. [25] 2011 AAPs 1 74 M Gore TF 5 0 No No
TEVAR + PCI
Uchida et al. [26] 2010 Ascending
aorta rupture













































































































































































Two articles provided interesting data about 3 patients treated
with ascending aorta endograft implantation combined with per-
cutaneous coronary treatments [23, 25]. Moreover, Allen et al.
[15] reported 1 patient with severe aortic valve stenosis and con-
comitant acute ascending aorta penetrating ulcer with tampo-
nade. The case was successfully managed using a transapical
aortic valve replacement combined with an endovascular aorta
repair. Some patients also required IA stenting or additional left
common carotid artery stenting. However, the number of stents
used could not be assessed, because some authors did not report
these data.
Device selection and technical details
Details about endoaortic device type, size, location in the aorta
and related complications are shown in Table 3. One case report
and 2 retrospective studies did not provide details about the
stent graft type, numbers, sizes, proximal and distal position. A
total of 74 stent grafts were used, including 18 custom-designed,
53 off-the-shelf and 3 modified-design stent grafts. The majority
of the stent grafts were placed between the origin of the coro-
nary artery or the proximal vein graft anastomosis (redo coronary
patients) and the IA. The origin of the IA was covered in 3 cases,
and the left carotid artery was covered in 1 case. In 3 cases, the
distal portion of the endograft was placed distally from the origin
of the left subclavian artery. In these 7 cases, the IA stenting, the
left carotid stenting or a surgical carotid–carotid bypass were
also performed.
The average length of the stent grafts was 66.9 ± 25.9mm
(range 28.5–150mm). The average distance between the coro-
nary ostia and the origin of the IA was 80.4 ± 16.7mm (range 33–
105mm) in 27 reported cases. The diameter of the ascending
aorta was 39.8 ± 17.2mm (range 22–94mm) as reported in 39
cases. Only 12 cases recorded the diameter of the sinotubular
junction and distal ascending aorta diameter. Unfortunately, ana-
tomical parameters of the aortic root were missing in 55 cases. In
addition, the measurement method in each case study was differ-
ent (Table 3).
Clinical outcomes
Complications related to the endovascular ascending aorta
repairs included endoleak (9 cases), stroke (3 cases), non-ST-ele-
vation myocardial infarction (1 case) and splenic infarction (1
case) (Fig. 3). Endoleaks were the most common complication
(13.4%): 7 cases were managed conservatively, whereas 2 cases
required reinterventions. Three postoperative strokes (4.8%), 1
non-ST-elevation myocardial infarction (1.5%) and 1 splenic
infarction (1.5%) were monitored closely. Six patients (8.9%)
required reintervention after endovascular repair: 5 patients
required open surgery (1 patient was operated for debranching
because of Type Ib endoleak and 2 patients required surgery
because of misplacement of the cuff of the stent graft in the
proximal aortic arch) and 1 patient underwent endovascular rein-
tervention for an endoleak.
The overall hospital mortality was 2.9% (2 patients died). One
patient with a pseudoaneurysm died on postoperative Day 14 of
respiratory failure and ventricular fibrillation. Another patient
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left ventricle due to the stiff guidewire during the procedure.
Emergency sternotomy was performed, and the rupture site was
secured. However, the patient died of multiple organ failure 24 h
later. During the follow-up period, the patient with stroke and
splenic infarction complications died of sudden death after
6months. Unfortunately, an autopsy was not performed.
DISCUSSION
Non-dissected ascending aorta disease should be managed proac-
tively because of the risk for acute life-threatening complications
and risk for rupture despite optimal medical therapy [10, 16].
However, open repair of the ascending aorta carries a higher risk
when performed in elderly high-risk patients, and, therefore,
endovascular treatments could be a valid option in these selected
cases [1]. Since the first reported case of endovascular repair of the
ascending aorta by Dorros et al. [2] in 2000, endovascular
treatment has become a potential alternative to open-heart sur-
gery in selected high-risk or inoperable patients.
Outcomes
Piffaretti et al. [10] recently reported a large case series of 8
patients with pseudoaneurysms and penetrating ulcers who
underwent total endovascular repair of the ascending aorta. In
this report, no endovascular-related hospital mortality, conver-
sion to surgery, cerebrovascular accidents, valve damage or myo-
cardial infarction occurred. A low-flow Type III endoleak was
detected in 1 patient who remained asymptomatic and was man-
aged conservatively. All patients were discharged home after a
mean length of stay of 6 days. No endograft malfunction, rupture
or migration was observed, and 87.5% of aortic lesions had a sig-
nificant reduction in diameter (>_5mm) at 1-year follow-up.
Other reports were analysed in this review, and the preliminary
results seem to be promising with low rate of major
Table 2: Outcomes of published cases of endovascular treatment for ascending aorta disease
AA disease Cases Percentage Complications Hospital mortality
AA aneurysm 11 16.4 1 endoleak 1 (9.1)
2 strokes
1 splenic infarction
AAPs 44 65.7 6 endoleak 1 (2.3)
1 stroke
1 NSTEMI
PAUs 6 8.9 2 endoleak 0
AA thrombosis 2 2.9 None 0
AA rupture 1 1.5 None 0
Iatrogenic coarctation 1 1.5 None 0
AA IMH 2 2.9 None 0
Total 67 14 (20.9) 2 (2.9)
Values are expressed as n (%) or mean ± SD.
AA: ascending aorta; AAPs: ascending aorta pseudoaneurysms; IMH: intramural haematoma; NSTEMI: non-ST-elevation myocardial infarction; PAUs: pene-
trating aortic ulcers; SD: standard deviation.
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Table 3: Technical details of the devices used for proximal endovascular aortic procedures and data of ascending aorta anatomy



















AA thrombosis CM 1 DOCA POIA 56 39
AAPs OS 1 DOCA POIA 28.5 33 28.5 33
PAU CM 1 DOCA POIA 60 38 38 60 37.2
AAPs CM 1 DOCA POIA 80 36 36 80 54.7
AAPs CM 1 DOCA POIA 60 34 34 60 37.4
AAPs CM 1 DOCA POIA 60 40 40 60 94.1
AAPs OS 2 DOCA POIA
AAPs MD 1 45 100
AAPs CM 1 DOCA POIA 65 30 65 70 26
AAPs OS 3 DOCA POIA 45 36 45 80 30
PAU OS 1 DOCA POIA 50 45 50 75 35
PAU OS 1 DOCA POIA 60 45 60 83 41
AAPs OS 2 DOCA POIA 60 45 60 90 37
AAPs OS 1 DOCA POIA 70 45 70 80 39
AAPs CM 1 DOCA POIA 70 38–48 70 70 22
PAU OS 4 DOCA POIA 45 36 45 48 29
AAA CM 2 DOCA POIA 67 36 67
38 67
AAPs CM 2 DOCA POIA 77 38 77
AAPs CM 2 DOCA POIA 77 38 77
AAPs OS 1 DOCA COIA 55 22 55
AAPs MD 2 DOCA POIA 70 40 40 70
OS 52 46 46 52
AAPs (9 cases) 90.3 ± 10 62 ± 8 36 ± 3 50 ± 10
PAU +AS MD 2 DOCA POIA 80 46 80
OS 100 45 100
AAPs OS 2 DOCA COIA 33 28 33
AAPs OS 1 DOCA POIA 100 34 100
AAPs OS 2 DOCA POIA 75 36 75
100 37 100
AAPs OS 1 DOCA POIA 100 28 100
AAPs OS 2 DOCA COIA and
2COLCCA
100 40 100
AAPs OS 1 DOCA POIA 100 40 100
AAPs OS 2 DOCA POIA 45 32 45
AAA CM 2 DOVG POIA 42 34 42
AAA CM 1 DOVG POIA 44 38 44
AAA OS 2 DOCA DOLSA 150 46 46 150
46 46 100
AAPs OS 1 DOCA POIA 45 34 45 78
AAPs OS 2 DOCA POIA 45 32 45 85 25 28 36
AAPs OS 1 DOCA POIA 33 28.5 33
AAPs OS 3 DOCA POIA 54 28 54
33 28 33
AAPs OS 1 DOCA POIA 64 34 64
AAPs OS 2 DOCA POIA 33 26 33 48 24.6
28.5 33
AAPs OS 2 DOCA POIA 26NA
AAPs OS 2 DOCA POIA 45 31.5 45 85 29
AAPs OS 1 DOCA POIA 100 40 100 105 38
AA disease (11 cases) DOCA 100.9 68.1
AAPs OS 1 DOCA POIA 100 40 100 105 38
AA rupture CM 1 DOCA DOLSA
AAPs OS 1 DOCA COLCCA 100 32 100
AAPs OS 2 DOCA POIA 77 38 77 77 31 34
AAPs CM 1 DOCA DOLSA 85 41 41
AAPs OS 3 DOCA POIA 36 32 36 60 30
Total CM=18 74 67 ± 26 80 ± 17 40 ± 17
OS = 53
MD= 3
Values are expressed as n (%) % or mean ± SD. Empty entries represent not available record.
AA: ascending aorta; AAA: ascending aorta aneurysm; AAPs: ascending aortic pseudoaneurysms; AS: Aortic Stenosis; CM: custom-made; COIA: covering the
origin of the IA; COLCCA: covering the origin of the LCCA; DOCA: distal to the origin of the coronary artery; DOVG: distal to the origin of the vein graft;
DOLSA: distally to the origin of the LSA or the proximal descending aorta; IA: innominate artery; IMH: intramural haematoma; LSA: left subclavian artery;
LCCA: left common carotid artery; MD: modified design in the operating room; NA: not available; OS: off-the-shelf; PAU: penetrating aortic ulcers; POIA: prox-
imal to the origin of the innominate artery; SD: standard deviation; STJ: sinotubular junction.
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complications and mortality (2.9% of mean in-hospital mortality).
However, there could be a risk of publication bias, because we
based our analysis on published small case series and case
reports, and, therefore, unsuccessful cases might have not been
reported by other authors.
All publications concluded that the endovascular repair of the
ascending aorta is a feasible, safe and effective method for treating
ascending aorta aneurysm, pseudoaneurysms and penetrating
aortic ulcers in high-risk or inoperable patients. Nevertheless, a
word of caution is required. In a selected subset of patients with
lesions, acceptable mid-term results were obtained with both
standard and custom-designed endografts. It is worth mentioning
that significant variability exists, both anatomically and physiologi-
cally, in patient selection. Careful sample selection is required
before drawing any conclusions from the presented data [4].
Access route
As to the access route, the retrograde transfemoral and trans-
subclavian approaches were the most commonly used access
sites, in particular when standard thoracic endoprosthesis and
delivery systems were used. However, many authors agree that
the transapical access offers more advantages when operating on
the ascending aorta, although it is more invasive and requires
cardiac surgery skills to be performed (we aim to underline the
importance of a Heart Team on-site) [12, 13, 15]. Transapical
access provides a short working distance to the ascending aorta
and addresses the inadequate length of current delivery systems,
giving the operator a significantly higher degree of device control
during the device deployment and, therefore, enabling a more
precise landing.
Endoleak
Another issue of endovascular procedures is the endoleak. In the
reported cases, the endoleak rate was 13.4% including Type Ia,
Type Ib and Type III endoleak. Luckily, the majority were small
endoleaks managed conservatively. Six (8.9%) patients required
reintervention by means of an endovascular procedure or open
surgery. Again, we should remember that these data come from
a small group of patients with short follow-up, and some endo-
leak can also appear years later.
The devices
Because of the complex anatomy, physiology and pathology of
the ascending aorta, the endovascular treatment of the ascending
aorta is more challenging than TEVAR of the aortic arch,
descending aorta or abdomen aorta. In particular, the difference
between the outer and the inner curve of the ascending aorta,
the 3D motion of the ascending aorta, the distance between the
sinotubular junction and the IA, the coronary ostia level and also
the presence of a concomitant aortic valve disease can make the
design of the ascending aorta endovascular device a challenge.
Moreover, the endovascular device requires a healthy segment of
proximal aorta for sealing and fixation but in patients with
ascending aorta disease there is merely enough healthy aorta.
Thus, patient selection is crucial for aligning aortic anatomy with
specific device designs.
So far, only isolated aortic diseases located between the sino-
tubular junction and the origin of the IA (with no involvement of
the aortic valve and the aortic root) may be treated with the
available endovascular graft technology. As a matter of fact, in
these 67 reported cases, the endovascular device was mainly
located between the coronary ostia and the IA, and in 7 patients,
the origin of the IA, left common carotid artery or left subclavian
artery was covered by the graft. Therefore, another major issue is
the absence, for the time being, of specifically designed stent
graft devices and dedicated delivery systems for the ascending
aorta. Currently available stent grafts for endovascular treatment
of ascending aorta disease are thoracic endografts that do not
fulfil the requirements for placement in the ascending aorta anat-
omy. They are, unfortunately, too long to be deployed between
the coronary arteries and the IA, and therefore, many surgeons
shortened the thoracic endografts on the operating table before
deployment into the ascending aorta [9, 13, 15].
Future perspectives
The design and manufacturing challenges to this problem are
much more complicated than simply making shorter grafts or
longer cuffs or altering the nose cones of the currently available
devices. The anatomical and physiological complexity of the
ascending aorta is different from that of the descending thoracic
or abdominal aorta. To extend the proximal landing zone to the
aortic root and aortic valve annulus, device modifications are
much needed to address the problem of the valve performance
and coronary perfusion.
CONCLUSION
Despite its advantages, the endovascular treatment can be
applied to the ascending aorta to a limited extent because of the
anatomical and physiological challenges. The available literature
on endovascular treatment of ascending aortic disease still con-
sists of single case reports or small case series with a few studies
Figure 3: List of complications occurred after endovascular ascending aorta
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describing the short- and mid-term outcomes. The follow-up
length is, for the time being, too short to draw conclusions con-
cerning the reliability of the endovascular technique for ascend-
ing aorta diseases. Therefore, general conclusion from solid
statistical analysis with adequate samples is lacking. Although the
safety and effectiveness of endovascular graft technology in
ascending aorta disease need further studies, the feasibility and
the advantages of this technique are becoming widely accepted
in selected cases. Indeed, clinical trials with large samples are
needed. Several technical problems including the development
of specific device designs that preclude the wide application of
this procedure must be solved. As the understanding of user and
market needs of endovascular treatment device will increase, the
technical problems will be resolved step by step. Also catheter-
based treatments will become the mainstream option for future
cardiac operations including ascending aortic lesions.
Conflict of interest: none declared.
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